IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by National Bank of Canada FI

National Bank of Canada FI cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 54.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 82,668 shares of the medical research company’s stock after selling 98,755 shares during the quarter. National Bank of Canada FI’s holdings in IQVIA were worth $16,245,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in IQV. Pine Valley Investments Ltd Liability Co grew its position in IQVIA by 0.5% in the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after acquiring an additional 50 shares during the period. Howard Capital Management Inc. grew its holdings in shares of IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after purchasing an additional 54 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in IQVIA by 1.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock valued at $1,068,000 after buying an additional 56 shares during the period. Cypress Wealth Services LLC lifted its position in IQVIA by 4.8% in the fourth quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after buying an additional 57 shares during the last quarter. Finally, Harbor Investment Advisory LLC boosted its stake in IQVIA by 4.7% during the fourth quarter. Harbor Investment Advisory LLC now owns 1,286 shares of the medical research company’s stock worth $253,000 after buying an additional 58 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

IQV has been the topic of several recent analyst reports. Barclays decreased their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Stifel Nicolaus decreased their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Bank of America dropped their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research note on Friday, December 13th. Citigroup decreased their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $263.00 target price (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Performance

Shares of IQV opened at $154.63 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52-week low of $154.35 and a 52-week high of $252.88. The stock has a 50 day moving average price of $189.67 and a 200 day moving average price of $204.07. The company has a market capitalization of $27.26 billion, a price-to-earnings ratio of 20.62, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.